Here's Why We're Not Too Worried About Jasper Therapeutics' (NASDAQ:JSPR) Cash Burn Situation [Yahoo! Finance]
Jasper Therapeutics, Inc. - Class A (JSPR)
Company Research
Source: Yahoo! Finance
lost money for years while it grew recurring revenue, if you held shares since 2005, you'd have done very well indeed. But while history lauds those rare successes, those that fail are often forgotten; who remembers Pets.com? So should Jasper Therapeutics NASDAQ:JSPR ) shareholders be worried about its cash burn? In this article, we define cash burn as its annual (negative) free cash flow, which is the amount of money a company spends each year to fund its growth. The first step is to compare its cash burn with its cash reserves, to give us its 'cash runway'. See our latest analysis for Jasper Therapeutics Does Jasper Therapeutics Have A Long Cash Runway? A cash runway is defined as the length of time it would take a company to run out of money if it kept spending at its current rate of cash burn. When Jasper Therapeutics last reported its March 2024 balance sheet in May 2024, it had zero debt and cash worth US$118m. In the last year, its cash burn was US$58m. So it had a cash
Show less
Read more
Impact Snapshot
Event Time:
JSPR
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
JSPR alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
JSPR alerts
High impacting Jasper Therapeutics, Inc. - Class A news events
Weekly update
A roundup of the hottest topics
JSPR
News
- Jasper Therapeutics, Inc. (NASDAQ: JSPR) is now covered by analysts at Stifel Nicolaus. They set a "buy" rating and a $86.00 price target on the stock.MarketBeat
- Jasper Therapeutics Announces Appointment of Svetlana Lucas Ph.D., to its Board of DirectorsGlobeNewswire
- Jasper Therapeutics, Inc. (NASDAQ: JSPR) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald.MarketBeat
- Jasper Therapeutics to Present at the Oppenheimer Novel Targets in Immunology SummitGlobeNewswire
- Jasper Therapeutics Presents Data from Preclinical Briquilimab Study at the 2024 EHA Hybrid Congress [Yahoo! Finance]Yahoo! Finance
JSPR
Earnings
- 5/14/24 - Beat
JSPR
Sec Filings
- 6/20/24 - Form 4
- 6/20/24 - Form 3
- 6/20/24 - Form 8-K
- JSPR's page on the SEC website